Extracellular vesicles LsEVs of lactobacillus salivarius LZZAY01 and application of extracellular vesicles LsEVs in colon cancer

The saliva isolated from the saliva of Xinjiang black chicken combined with the extracellular vesicles of LZZAY01 of Lactobacillus LZZAY01 was solved, and the problem of unstable activity of probiotics in the gastric acid environment was achieved, effectively treating colon cancer and normal intestinal epithelial cells. Promote growth.

CN119060911APending Publication Date: 2024-12-03INNER MONGOLIA MEDICAL UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411450036.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-17
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing probiotics are difficult to tolerate harsh gastric acid environment when transported to the intestines, resulting in the inability to guarantee the number of effective live bacteria, which in turn affects its effectiveness in the treatment of colon cancer.

Method used

The extracellular vesicles LsEVs of saliva combined with Lactobacillus LZZAY01 were developed. The extracellular vesicles with spherical bilayer membrane structures with a particle size of 100-300nm were isolated from the saliva of Xinjiang black chickens through a specific extraction method and applied to the Treatment of colon cancer.

Benefits of technology

Extracellular vesicles LsEVs of saliva combined with Lactobacillus LZZAY01 showed anti-colon cancer function in in vitro and promoted normal intestinal epithelial cell growth in vitro, providing new ideas and ways to treat colon cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060911A_ABST
    Figure CN119060911A_ABST
Patent Text Reader

Abstract

The invention provides extracellular vesicles LsEVs of Lactobacillus salivarius LZZAY01 and application of the extracellular vesicles LsEVs in colon cancer, the Lactobacillus salivarius LZZAY01 is separated from saliva of Xinjiang black chicken, the extracellular vesicles LsEVs are secreted by the Lactobacillus salivarius LZZAY01, and the extracellular vesicles LsEVs are of a spherical double-layer membrane structure with the particle size of 100-300 nm; the extracellular vesicles of the lactobacillus salivarius LZZAY01 are researched and developed, the colon cancer resisting function of the extracellular vesicles is observed in in-vivo and in-vitro experiments, growth of normal intestinal epithelial cells is promoted in vitro, and a new thought and approach are provided for application of the probiotic extracellular vesicles in cancer resisting and inhibiting.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to extracellular vesicles LsEVs of saliva combined with lactobacillus LZZAY01 and application thereof in colon cancer, belonging to the technical field of microorganisms. Background Art

[0002] Colon cancer is one of the malignant tumors of the digestive tract with the highest morbidity and mortality in the world, and it poses a serious threat to human health. Colon cancer is usually the result of the interaction of multiple complex factors such as the intestinal microbiota, mucosal barrier, environment, and immune system, and its prevention and treatment face huge challenges. In recent years, the interaction between probiotics, the host, and the intestinal microbiota has gradually become clear. Treatment methods such as positive regulation of the intestinal microbiota, enhancement of the intestinal mucosal barrier, competitive inhibition, or elimination of pathogenic bacteria through oral probiotics have been recognized by many researchers. However, most probiotics are difficult to tolerate the harsh gastric acid environment after oral administration, resulting in a lack of guarantee for the number of effective live bacteria delivered to the intestine.

[0003] Probiotic extracellular vesicles (EVs) can be regarded as a safe and effective communication carrier to provide beneficial effects for probiotics. Probiotic extracellular vesicles (EVs) can carry their biologically active components, pass through the mucus layer and migrate directly to other tissues or interact with different cells of the host immune system to exert biological functions. Therefore, probiotic-derived EVs are expected to become a new and safe strategy for the treatment of colon cancer in clinical practice.

[0004] However, there is no research on probiotic extracellular vesicles (EVs). Based on this, we developed extracellular vesicles (LsEVs) of saliva combined with Lactobacillus LZZAY01 and their application in colon cancer. Summary of the invention

[0005] The invention discloses an extracellular vesicle LsEVs of saliva-associated Lactobacillus LZZAY01. The saliva-associated Lactobacillus LZZAY01 is isolated from the saliva of a Xinjiang black chicken, has a deposit number of CGMCC NO:28400, a deposit date of September 8, 2023, and a deposit unit of the General Microbiological Center of China National Committee for the Preservation of Microorganisms. The 16S rDNA sequence is shown in SEQ ID NO:1, and the classification name is Ligilactobacillus salivarius. The extracellular vesicle LsEVs is secreted by the saliva-associated Lactobacillus LZZAY01. The extracellular vesicle LsEVs has a spherical double-layer membrane structure with a particle size of 100-300 nm.

[0006] Moreover, the extracellular vesicles LsEVs were extracted using a bacterial membrane vesicle isolation kit (dlmbiotech, BacMV10-20), and the extraction method was as follows: S1. Collect bacterial culture supernatant (1) Pick a single colony of saliva-associated Lactobacillus LZZAY01 and place it in MRS broth, place it on a constant temperature shaker and shake for 10-14 hours, collect the bacterial liquid, and centrifuge it at 5000×g and 4℃ for 15-25 minutes to obtain a primary supernatant; (2) Take the first supernatant and centrifuge it again at 5000×g and 4°C for 15-25 min to obtain the second supernatant; (3) Add 0.5 M / L NaOH to the secondary supernatant to adjust the pH to 7.0-7.4 to obtain a pH-adjusted secondary supernatant, which was stored at -20°C; S2. Extracellular vesicles LsEVs resin capture (1) Take 10 mL of the pH-adjusted secondary supernatant, add 1.0 mL of binding buffer, mix well, add 400 μL of binding resin, mix well, and centrifuge at 1500 × g for 1.5-2.5 min after 10-20 min to obtain the tertiary supernatant; (2) Take 400 μL of the binding resin, add the above three supernatants, mix at room temperature by inversion for 15 minutes, and centrifuge at 1,500×g for 2 minutes. Use a pipette to take 400 μL of the supernatant after centrifugation (do not discard), carefully pour out the remaining supernatant, use the 400 μL supernatant in the pipette to gently blow up the resin, transfer it to the purification column, let it stand for 1.5-2.5 minutes, centrifuge at 2000×g for 1.5-2.5 minutes, discard the filtrate, and put the purification column back into the collection tube; S3. Washing of extracellular vesicles LsEVs Take 500 μL of washing solution and add it to the purification column. Let it stand for 3 minutes, centrifuge at 3000×g for 1.5-2.5 minutes, discard the filtrate, and repeat the washing once; S4. Elution of extracellular vesicles (LsEVs) Place the purification column in a 1.5mL centrifuge tube with low protein adsorption, add 400μL of elution buffer, let stand for 5 minutes, centrifuge for 1.5-2.5 minutes, transfer the filtrate to the purification column, let stand at room temperature for 3-8 minutes, centrifuge for 1.5-2.5 minutes, and the liquid obtained by centrifugation is the extracellular vesicle LsEVs concentrate.

[0007] Furthermore, in step S1 (1), the temperature of the constant temperature shaker is 37° C. and the rotation speed is 200 rpm.

[0008] On the other hand, the present invention provides an application of extracellular vesicles LsEVs of saliva combined with Lactobacillus LZZAY01 for treating colon cancer.

[0009] Compared with the prior art, the present invention has the following beneficial effects: The present invention developed extracellular vesicles of saliva combined with Lactobacillus LZZAY01, and observed its anti-colon cancer function in in vivo and in vitro experiments, and promoted the growth of normal intestinal epithelial cells in vitro, which provides new ideas and approaches for the application of probiotic extracellular vesicles (EVs) in anti-cancer and tumor suppression. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figure 1 This is a transmission electron microscopic image of the extracellular vesicles LsEVs of saliva-associated Lactobacillus LZZAY01; Figure 2 A typical image of extracellular vesicles LsEVs characterized by nanoparticle tracking analysis technology; Figure 3 It is the particle size distribution and concentration peak diagram of extracellular vesicles LSEvs; Figure 4 This is the standard curve for measuring the protein content of extracellular vesicles LsEVs by BCA method; Figure 5 This is the result of Coomassie brilliant blue staining of extracellular vesicle LsEVs protein; Figure 6 To test the cytotoxicity of extracellular vesicles (LsEVs) to colon cancer cells and normal colon epithelial cells in vitro; Figure 7 The results of the in vivo experiment of using extracellular vesicles LsEVs in mice with colon cancer are shown in Figure 2. Figure 7 A is the construction of the animal model, 7B is a comparison of the colon of mice in the normal control group, model group and extracellular vesicle LsEVs treatment group, Figure 7 C is the comparison of the number of colon adenomas between the mice in the extracellular vesicle LsEVs treatment group and the model group, 7D is the changes in body weight of mice in the normal control group, model group and extracellular vesicle LsEVs treatment group, and 7E is the changes in colon length of mice in the normal control group, model group and extracellular vesicle LsEVs treatment group. DETAILED DESCRIPTION

[0011] Example 1 Extraction of extracellular vesicles from saliva combined with Lactobacillus LZZAY01 1. Collect bacterial culture supernatant Pick a single colony of saliva-associated Lactobacillus LZZAY01 into MRS broth, place it in a constant temperature shaker at 37°C, 200 rpm, shake overnight (12 h), collect the bacterial liquid, centrifuge it at 5,000×g, 4°C for 20 min, transfer the supernatant to a new centrifuge tube, centrifuge it again at 5,000×g, 4°C for 20 min to completely remove bacteria and bacterial fragments, collect the supernatant, adjust the pH to 7.0-7.4 with 0.5M / L NaOH, and store it at -20°C for use.

[0012] 2. Extracellular vesicles LsEVs resin capture Pipette 10mL of the collected supernatant into a 15mL centrifuge tube, add 1.0mL of binding buffer, invert to mix, add 400μL of binding resin, invert to mix at room temperature for 15min, centrifuge at 1500×g at room temperature for 1.5-2.5min, take 400μL of the supernatant after centrifugation, discard the remaining supernatant, use a pipette to obtain 400μL of liquid and gently blow up the resin, transfer all to the purification column, let it stand for 2min, centrifuge at 2000×g at room temperature for 1.5-2.5min, discard the filtrate, and put the purification column back into the collection tube.

[0013] 3. Washing of extracellular vesicles LsEVs Take 500 μL of washing solution and add it to the purification column. Let it stand for 3 minutes, centrifuge at 3000×g at room temperature for 1.5-2.5 minutes, discard the filtrate, and repeat the washing once.

[0014] 4. Elution of extracellular vesicles (LsEVs) Place the purification column in a 1.5mL centrifuge tube with low protein adsorption, add 400μL of elution solution, let stand at room temperature for 3-8min, centrifuge at 500×g for 1.5-2.5min, transfer the filtrate to the purification column, let stand at room temperature for 3-8min, centrifuge at 3,000×g for 1.5-2.5min. The liquid obtained by centrifugation is the extracellular vesicle concentrate of saliva combined with Lactobacillus LZZAY01, which is stored at -80℃ for subsequent experiments.

[0015] Example 2 Transmission electron microscopy detection of extracellular vesicles LsEVs 1. Adsorption: Prepare the extracellular vesicle suspension sample of saliva and Lactobacillus LZZAY01, use a pipette to draw 10ul of the suspension and drop it onto the prepared Parafilm sealing film (the back of the sealing film is adhered to the table), place the copper mesh with the front side facing down, let it naturally adsorb the suspension droplets for 10-15 minutes, then use filter paper strips to absorb excess droplets and let it dry slightly.

[0016] 2. Staining: Pipette 10ul of 2% phosphotungstic acid solution and drop it on the sealing film. Place the copper mesh with the front side facing the staining solution and turn it upside down and let it stand for 3-5 minutes.

[0017] 3. Drying: Use filter paper strips to absorb excess droplets and dry under incandescent light.

[0018] 4. Observation and photography: Observation and photography under a transmission electron microscope, such as Figure 1 shown.

[0019] Experimental results: From Figure 1 It can be seen that the ultrastructure of the purified extracellular vesicles LsEVs under transmission electron microscopy is an oval vesicle structure containing a double membrane, and the particle size is between 100-300nm.

[0020] Example 3 Nanoparticle Tracking Analysis Technology Purified extracellular vesicles LsEVs were added with 1×PBS to adjust to the appropriate concentration, and then loaded and detected using a nanoparticle tracking analyzer (Particle Metrix, PMX-120, GE). The real-time dynamic images of exosome particles were observed on the computer display screen, information was collected, and the acquired data were analyzed using Zetaview software.

[0021] Experimental results: Typical images of LsEVs characterized by NTA technology are shown in Figure 2. Figure 2 As shown in Figure 2, the particle size distribution and concentration of extracellular vesicles LSEvs were analyzed by Zetaview software. Figure 3 As shown, from Figure 2 , Figure 3 It can be seen that the LsEvs particles are evenly distributed and the peaks are relatively neat and uniform, which indicates that the extracellular vesicles LsEvs prepared in this experiment have a high purity. The particle detection concentration is 6.5×10 7 Particles / mL, dilution factor 500, original concentration 3.3×10 10 Particles / mL, the particle size of extracellular vesicles LsEvs is between 100-300nm, which is consistent with the results observed by our electron microscopy.

[0022] Example 4 Preparation and detection of extracellular vesicle LsEVs protein samples 1. Protein extraction The purified LsEVs sample was added with an equal volume of RIPA lysis buffer and lysed on ice for 30 min. The lysate was centrifuged at 12000×g for 20 min, the precipitate was discarded, and the supernatant was collected.

[0023] 2. Protein quantification by BCA method The protein content of the extracellular vesicles LsEVs samples was determined using a BCA protein quantification kit. A standard curve for protein quantification was first established according to the method provided in the kit instructions, and then the protein content of the sample was calculated based on the measured OD value.

[0024] 3. Protein electrophoresis and Coomassie Brilliant Blue staining SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis) was used to preliminarily detect the distribution of extracellular vesicles LsEVs proteins. The protein loading amount was 20 μg, the gel concentration was 12%, and Coomassie brilliant blue staining was performed after electrophoresis.

[0025] Experimental results: The standard curve of the BCA method for measuring the protein content of LsEVs is as follows: Figure 4 As shown, the protein concentration range is 0-0.5 mg / ml, and the standard curve has a good linear relationship (R 2 =0.9954), according to the OD value of the extracellular vesicle LsEVs purified sample (OD value of extracellular vesicle LsEVs = 0.18, sample diluted 10 times, final concentration × 10), its protein content was measured to be about 1 mg / ml. The results of Coomassie brilliant blue staining of extracellular vesicle LsEVs protein are as follows Figure 5 As shown, the protein bands are relatively clear, mostly concentrated in the range of 33-43 kDa.

[0026] Example 5 Cytotoxicity Experiment CCK8 (Cell Counting Kit-8) was used to detect the effect of extracellular vesicles (LsEVs) on the proliferation activity of colon cancer cells and normal human colon epithelial cells. Three colon cancer cell lines, human colon cancer cell lines SW-620 and HCT-116, mouse colon cancer cell line CT-26, and human normal colon cancer epithelial cell line NCM-460 were cultured at 5×10 4 Cells were seeded at a density of 10 cells / ml in 96-well plates and exposed to different concentrations (0, 100, 150, 200, 250, 300 μl / ml) of extracellular vesicles (LsEVs) for 48 h.

[0027] 10 μl of CCK8 solution was added to a single well, and the cells were incubated in a 37°C incubator for 1 h. The absorbance at a wavelength of 450 nm was detected using a Multiskan GO full-wavelength microplate reader. Cell viability = OD (experimental group-control group) / OD (control group-blank group) × 100%.

[0028] Experimental results: It was observed under the microscope that extracellular vesicles LsEVs had a significant inhibitory effect on the proliferation of colon cancer cells. Figure 6As shown, as the concentration of LsEVs increased, the cell viability of the three colon cancer cells gradually decreased. When the concentration of LsEVs increased to 20%, the survival rate of colon cancer cells decreased significantly (p<0.05); however, after LsEVs acted on normal human colon epithelial cells for 48 hours, the proliferation of the NCM-460 cell line was not inhibited, and the survival rate increased (p<0.05). These results show that LsEVs can inhibit the proliferation activity of colon cancer cells HCT-116, SW-620 and CT-26 in vitro, and promote the proliferation of human normal colon cancer epithelial cell line NCM-460.

[0029] Example 6 In vivo experiment in mice The AOM / DSS method (azoxymethane combined with dextran sulfate sodium) was used to induce an inflammation-related colon cancer model in mice. Fifteen female C57BL / 6j mice (8 weeks old) were selected and kept at 22±2℃ and 30-70% relative humidity with alternating light and light for 12 hours. The mice were allowed to adapt to a free diet for one week, and then randomly divided into three groups (n=5 / group): a normal control group (treated with the same volume of saline only), an AOM / DSS model group (treated with AOM / DSS only), and an extracellular vesicle LsEVs treatment group (treated with AOM / DSS and gavage of extracellular vesicle LsEVs 200μl / mouse / day).

[0030] On the first day, 10 mg / kg AOM was injected intraperitoneally, and then 2.0% DSS was added to the drinking water every day for 1 week. In the next 2 weeks, normal drinking water was restored, and the cycle was repeated three times. In the last DSS cycle, the mice in the LsEVs treatment group were gavaged with LsEVs every day for three weeks, and there was a one-week adaptation period until the 11th week. The animal model was constructed as follows Figure 7 As shown in A.

[0031] Experimental results: The colon conditions of normal control mice, colon cancer model mice, and LsEVs-treated mice were as follows Figure 7 As shown in B, the body weight and colon length of mice in the extracellular vesicle LsEVs treatment group were increased compared with those in the model group ( Figure 7 D, E, p<0.05). At the same time, the number of colon adenomas in the extracellular vesicles LsEVs treatment group was significantly reduced compared with that in the model group ( Figure 7 C, p<0.05). These results indicate that LsEVs treatment of colon cancer mice can improve colon shortening in colon cancer mice and delay the progression of colon cancer in mice.

Claims

1. An extracellular vesicle LsEVs of saliva-associated Lactobacillus LZZAY01, wherein the saliva-associated Lactobacillus LZZAY01 is isolated from the saliva of Xinjiang black chicken, and its deposit number is CGMCC NO: 28400, the deposit date is: September 8, 2023, the deposit unit is: General Microbiology Center of China Microbiological Culture Collection Administration, the 16S rDNA sequence is shown in SEQ ID NO: 1, characterized in that, The extracellular vesicles LsEVs are obtained by secretion of saliva and lactobacillus LZZAY01, and the particle size of the extracellular vesicles LsEVs is a spherical double-layer membrane structure of 100-300nm.

2. The extracellular vesicles LsEVs of saliva-lactobacillus LZZAY01 according to claim 1, characterized in that: The extraction method of the extracellular vesicles LsEVs is as follows: S1. Collect bacterial culture supernatant (1) Pick a single colony of saliva-associated Lactobacillus LZZAY01 and place it in MRS broth, place it on a constant temperature shaker and shake for 10-14 hours, collect the bacterial liquid, and centrifuge it at 5000×g and 4℃ for 15-25 minutes to obtain a primary supernatant; (2) Take the first supernatant and centrifuge it again at 5000×g and 4°C for 15-25 min to obtain the second supernatant; (3) Add 0.5 M / L NaOH to the secondary supernatant to adjust the pH to 7.0-7.4 to obtain a pH-adjusted secondary supernatant, which was stored at -20°C; S2. Extracellular vesicles LsEVs resin capture (1) Take 10 mL of the pH-adjusted secondary supernatant, add 1.0 mL of binding buffer, mix well, add 400 μL of binding resin, mix well, and centrifuge at 1500 × g for 1.5-2.5 min after 10-20 min to obtain the tertiary supernatant; (2) Take 400 μL of the bound resin, add the above three supernatants, mix well, centrifuge at 1500×g for 2 minutes at room temperature after 15 minutes, take 400 μL of the supernatant after centrifugation with a pipette, blow up the resin, transfer to the purification column, let it stand for 1.5-2.5 minutes, centrifuge at 2000×g for 1.5-2.5 minutes, discard the filtrate, and put the purification column back into the collection tube; S3. Washing of extracellular vesicles LsEVs Take 500 μL of washing solution and add it to the purification column. Let it stand for 3 minutes, centrifuge at 3000×g for 1.5-2.5 minutes, discard the filtrate, and repeat the washing once; S4. Elution of extracellular vesicles (LsEVs) Place the purification column in a centrifuge tube with low adsorption protein, add elution solution, let stand for 5 minutes, centrifuge for 1.5-2.5 minutes, transfer the filtrate to the purification column, let stand at room temperature for 3-8 minutes, centrifuge for 1.5-2.5 minutes, and the liquid obtained by centrifugation is the extracellular vesicle LsEVs concentrate.

3. The extracellular vesicles LsEVs of saliva-lactobacillus LZZAY01 according to claim 2, characterized in that: In step S1 (1), the temperature of the constant temperature shaker is 37° C. and the rotation speed is 200 rpm.

4. Use of the extracellular vesicles LsEVs of saliva combined with Lactobacillus LZZAY01 as described in any one of claims 1 to 3.

5. The use of the extracellular vesicles LsEVs of saliva combined with Lactobacillus LZZAY01 as claimed in claim 4, characterized in that: Used to treat colon cancer.

Citation Information

Cited By

  • Application of human beta-defensin-1 combined alphaPD-1 antibody in preparation of immunomodulatory medicine for treating or preventing colon cancer

    CN120478620A